IOncology

From September 25 to 29, 2024, the highly anticipated 27th Chinese Clinical Oncology Annual Conference and CSCO Annual Meeting took place in Xiamen. Dr. Rongbo Lin of Fujian Cancer Hospital shared key findings from his team’s research in gastric cancer. During the conference, Oncology Frontier conducted an in-depth interview with Professor Lin, discussing the clinical applications of the POFI and POF regimens for advanced gastric cancer.

Despite ctDNA’s nascent role in treatment decision-making, it is a proven marker of MRD in CRC patients, and research increasingly explores its role in guiding treatment across gastrointestinal cancers. At the 2024 ASCO Gastrointestinal Cancers Symposium, Dr. Pashtoon M. Kasi from Weill Cornell Medicine and Dr. Jeanne Tie from the Peter MacCallum Cancer Centre presented findings from two clinical trials investigating ctDNA in CRC adjuvant chemotherapy guidance.

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Alyson B. Moadel from the Albert Einstein Montefiore Medical Center unveiled a study on artificial intelligence (AI). The findings demonstrated that an AI-based patient navigation tool effectively assisted patients who missed initial colonoscopy appointments, significantly increasing screening completion rates. Recently, Dr. John Sweetenham from the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center provided insights on this groundbreaking study. This article presents a detailed view of this leading-edge research and its profound implications for healthcare.

At the 2024 ASCO Annual Meeting, a groundbreaking study led by Dr. Martijn Ruben Meijerink from Amsterdam University Medical Center focused on thermal ablation versus surgery for small colorectal liver metastases. This study has the potential to change clinical practice. Dr. Shaalan Beg from the Simmons Comprehensive Cancer Center at the University of Texas Southwestern Medical Center recently shared his insights on this noteworthy research in ASCO Daily News. This article presents the study’s key findings and its implications in the medical field.

The 27th Annual Conference of the Chinese Society of Clinical Oncology (CSCO) took place in Xiamen from September 25–29, 2024. This year’s theme, “Patient-Centered, Sharing the Future,” brought together groundbreaking research and developments. Dr. Lei Tang from Peking University Cancer Hospital delivered an insightful presentation on the current state and challenges of imaging in evaluating gastric cancer immunotherapy. In a post-conference interview, he discussed key aspects of imaging evaluation for immunotherapy in gastric cancer.

The 2024 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2024) took place in San Francisco from January 18-20, gathering top experts from around the world to share the latest advances in gastrointestinal cancer research. Dr. Zhi Peng from Peking University Cancer Hospital presented two studies (Abstracts 312 and 317) in the poster session, showcasing the contributions of Chinese researchers on the international stage. In an exclusive interview with Oncology Frontier, Professor Peng shared insights on his studies and perspectives on gastric cancer diagnosis and treatment.

The field of second-line treatment for advanced gastric cancer is a current focal point in oncology research. On February 6, 2024, during the ASCO Plenary Series, Dr. Ruihua Xu from Sun Yat-sen University Cancer Center presented findings from the FRUTIGA study (NCT03223376), a phase III trial conducted in China evaluating the efficacy of fruquintinib combined with paclitaxel for second-line treatment in advanced gastric cancer. The study offers an additional treatment option for advanced gastric cancer. Oncology Frontier highlighted perspectives from Dr. Ruihua Xu and Dr. Florian Lordick, Director of the University Cancer Center Leipzig, on the significance of FRUTIGA. Here’s a summary of the discussion.

On October 18, 2024, the 18th National Breast Cancer Conference and the 19th Shanghai International Breast Cancer Forum grandly opened, gathering significant global advancements in breast cancer. In the era following CDK4/6 inhibitors for hormone receptor-positive (HR+) breast cancer, targeted endocrine therapies based on the PIK3CA/AKT1/PTEN pathway have brought new hope to patients. At this conference, Dr. Virginia Kaklamani from The University of Texas MD Anderson Cancer Center shared important insights on the progress of treating HR+ metastatic breast cancer and discussed post-CDK4/6 inhibitor strategies and clinical practice experiences for HR+ advanced breast cancer in the "Viewpoint · SIBCS Special" column of Oncology Horizon.

For patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), dual inhibition of EGFR and MET may be the most effective strategy after disease progression on osimertinib, particularly for patients with MET gene amplification (METamp). Dr. Benjamin Besse, Dr. Lodovica Zullo, and Dr. Jordi Remon from the Gustave Roussy Institute analyze therapeutic strategies for METamp-driven resistance following osimertinib treatment in this article.

Breast reconstruction surgery offers hope for patients to regain confidence and beauty in the field of breast cancer treatment. With advances in medical technology, implant-based breast reconstruction has become a mainstream choice. However, complications related to implants remain a key concern for both surgeons and patients. At the 16th Shanghai Breast Reconstruction Conference, Dr. Benlong Yang from the Breast Surgery Department of Fudan University Shanghai Cancer Center led a session discussing "Implant Complications." Following the event, Oncology Frontier interviewed Dr. Yang to delve into key issues surrounding implant reconstruction.